

Chiara Gabbiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6447899/publications.pdf>

Version: 2024-02-01

105
papers

6,392
citations

57631

44
h-index

69108

77
g-index

109
all docs

109
docs citations

109
times ranked

5724
citing authors

#	ARTICLE	IF	CITATIONS
1	Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins. <i>Molecules</i> , 2021, 26, 2376.	1.7	7
2	A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes. <i>Journal of Inorganic Biochemistry</i> , 2021, 217, 111355.	1.5	29
3	Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study. <i>Inorganica Chimica Acta</i> , 2021, 520, 120297.	1.2	12
4	On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules. <i>Molecules</i> , 2020, 25, 5446.	1.7	11
5	¹²⁴ I Radiolabeling of a Au ^{III} NHC Complex for In Vivo Biodistribution Studies. <i>Angewandte Chemie</i> , 2020, 132, 17278-17284.	1.6	5
6	Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study. <i>Frontiers in Chemistry</i> , 2020, 8, 812.	1.8	31
7	¹²⁴ I Radiolabeling of a Au ^{III} NHC Complex for In Vivo Biodistribution Studies. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 17130-17136.	7.2	17
8	Cytotoxic Ag(I) and Au(I) NHC-carbenes bind DNA and show TrxR inhibition. <i>Journal of Inorganic Biochemistry</i> , 2020, 205, 110998.	1.5	37
9	Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis. <i>Journal of Inorganic Biochemistry</i> , 2020, 209, 111096.	1.5	22
10	Interplay between Gold(I)-Ligand Bond Components and Hydrogen Bonding: A Combined Experimental/Computational Study. <i>ACS Omega</i> , 2019, 4, 1344-1353.	1.6	5
11	Photocytotoxic Pt(IV) complexes as prospective anticancer agents. <i>Dalton Transactions</i> , 2019, 48, 10933-10944.	1.6	28
12	Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand. <i>Journal of Inorganic Biochemistry</i> , 2018, 183, 101-106.	1.5	8
13	Interaction of a gold(I) dicarbene anticancer drug with human telomeric DNA G-quadruplex: solution and computationally aided X-ray diffraction analysis. <i>Dalton Transactions</i> , 2018, 47, 16132-16138.	1.6	35
14	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. <i>Inorganica Chimica Acta</i> , 2018, 470, 318-324.	1.2	8
15	Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study. <i>Oncotarget</i> , 2018, 9, 28042-28068.	0.8	53
16	Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. <i>Talanta</i> , 2017, 167, 30-38.	2.9	30
17	Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents. <i>BioMetals</i> , 2017, 30, 313-320.	1.8	24
18	Ruthenium arene complexes with triphenylphosphane ligands: cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution. <i>New Journal of Chemistry</i> , 2017, 41, 14574-14588.	1.4	37

#	ARTICLE	IF	CITATIONS
19	Auranofin, Et ₃ PAuCl, and Et ₃ PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. ACS Medicinal Chemistry Letters, 2017, 8, 997-1001.	1.3	91
20	ESI-MS studies of the reactions of novel platinum(II) complexes containing O,O ² -chelated acetylacetonate and sulfur ligands with selected model proteins. BioMetals, 2017, 30, 609-614.	1.8	12
21	Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties. European Journal of Inorganic Chemistry, 2017, 2017, 1737-1744.	1.0	17
22	Anticancer Gold N-Heterocyclic Carbene Complexes: A Comparative in-vitro and ex-vivo Study. ChemMedChem, 2017, 12, 1429-1435.	1.6	52
23	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. Journal of Inorganic Biochemistry, 2016, 163, 318-322.	1.5	5
24	First Crystal Structure for a Gold Carbene-Protein Adduct. Bioconjugate Chemistry, 2016, 27, 1584-1587.	1.8	27
25	Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles. BioMetals, 2016, 29, 535-542.	1.8	13
26	Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles. BioMetals, 2016, 29, 863-872.	1.8	22
27	cis-Pt I ₂ (NH ₃) ₂ : a reappraisal. Dalton Transactions, 2015, 44, 14896-14905.	1.6	45
28	Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipy _c in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. Molecular BioSystems, 2015, 11, 1653-1667.	2.9	10
29	Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation. BioMetals, 2015, 28, 1079-1085.	1.8	4
30	Nitrate as a probe of cytochrome c surface: Crystallographic identification of crucial "hot spots" for protein-protein recognition. Journal of Inorganic Biochemistry, 2014, 135, 58-67.	1.5	11
31	Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. Dalton Transactions, 2014, 43, 3072-3086.	1.6	34
32	Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. Journal of Inorganic Biochemistry, 2014, 141, 79-82.	1.5	27
33	Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation. Journal of Inorganic Biochemistry, 2014, 136, 161-169.	1.5	88
34	Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc. Journal of Proteomics, 2014, 103, 103-120.	1.2	37
35	Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents. Inorganic Chemistry, 2014, 53, 2396-2403.	1.9	79
36	The mode of action of anticancer gold-based drugs: a structural perspective. Chemical Communications, 2013, 49, 10100.	2.2	76

#	ARTICLE	IF	CITATIONS
37	Metal-Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes. <i>ChemMedChem</i> , 2013, 8, 1634-1637.	1.6	32
38	Butyltin(IV) Benzoates: Inhibition of Thioredoxin Reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins. <i>ChemMedChem</i> , 2013, 8, 256-264.	1.6	27
39	Promising <i>in Vitro</i> anti-Alzheimer Properties for a Ruthenium(III) Complex. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 329-332.	1.3	61
40	The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. <i>Journal of Inorganic Biochemistry</i> , 2013, 118, 94-99.	1.5	38
41	Peculiar Features in the Crystal Structure of the Adduct Formed between <i>cis</i> -Pt ₂ (NH ₃) ₂ and Hen Egg White Lysozyme. <i>Inorganic Chemistry</i> , 2013, 52, 13827-13829.	1.9	56
42	Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. <i>Metallomics</i> , 2012, 4, 307.	1.0	39
43	2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. <i>Molecular BioSystems</i> , 2012, 8, 985-993.	2.9	30
44	Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 1293-1302.	1.1	50
45	Metal compounds as inhibitors of $\text{A}\beta$ -amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2012, 256, 2357-2366.	9.5	65
46	Synthesis, Structural Characterization, Solution Behavior, and <i>in Vitro</i> Antiproliferative Properties of a Series of Gold Complexes with 2-(2-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives. <i>Inorganic Chemistry</i> , 2012, 51, 3161-3171.	1.9	74
47	Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. <i>Chemical Communications</i> , 2012, 48, 11623.	2.2	32
48	Reactivity and Biological Properties of a Series of Cytotoxic Pt ₂ (amine) ₂ Complexes, Either <i>cis</i> or <i>trans</i> Configured. <i>Inorganic Chemistry</i> , 2012, 51, 1717-1726.	1.9	38
49	Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents. <i>Inorganica Chimica Acta</i> , 2012, 393, 115-124.	1.2	28
50	Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties. <i>Journal of Inorganic Biochemistry</i> , 2012, 108, 123-127.	1.5	34
51	Exploring the Reactions of $\text{A}\beta$ Peptide 1-28 with Alkylated Fe(III) Ions. <i>Inorganic Chemistry</i> , 2011, 50, 6865-6867.	1.9	42
52	Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(ii) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. <i>Metallomics</i> , 2011, 3, 987-990.	1.0	10
53	Thioredoxin reductase, an emerging target for anticancer metallodrugs. Enzyme inhibition by cytotoxic gold(III) compounds studied with combined mass spectrometry and biochemical assays. <i>MedChemComm</i> , 2011, 2, 50-54.	3.5	94
54	Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. <i>Metallomics</i> , 2011, 3, 1318.	1.0	29

#	ARTICLE	IF	CITATIONS
55	Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. Dalton Transactions, 2011, 40, 2006.	1.6	27
56	Aluminum, copper, iron and zinc differentially alter amyloid- $A\beta$ 42 aggregation and toxicity. International Journal of Biochemistry and Cell Biology, 2011, 43, 877-885.	1.2	147
57	Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. Journal of Inorganic Biochemistry, 2011, 105, 1576-1579.	1.5	19
58	Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones. Bioorganic and Medicinal Chemistry, 2011, 19, 631-641.	1.4	11
59	Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. Journal of Inorganic Biochemistry, 2011, 105, 348-355.	1.5	40
60	Protein Targets for Anticancer Gold Compounds: Mechanistic Inferences. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 929-939.	0.9	32
61	Trace Copper(II) or Zinc(II) Ions Drastically Modify the Aggregation Behavior of Amyloid- $A\beta$ 42: An AFM Study. Journal of Alzheimer's Disease, 2010, 19, 1323-1329.	1.2	81
62	Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. Journal of Biological Inorganic Chemistry, 2010, 15, 573-582.	1.1	60
63	Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discovery Today, 2010, 15, 1070-1078.	3.2	193
64	Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Medicinal Research Reviews, 2010, 30, 550-580.	5.0	431
65	Trans- <i>cis</i> -[RuCl ₂ (DMSO) ₂ (2-amino-5-methyl-thiazole) ₂], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. Journal of Inorganic Biochemistry, 2010, 104, 111-117.	1.5	16
66	New platinum-oxo complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. Journal of Inorganic Biochemistry, 2010, 104, 799-814.	1.5	50
67	Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 324-337.	0.9	31
68	Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel <i>trans</i> -iodoplatinum(II) Complex. ACS Medicinal Chemistry Letters, 2010, 1, 381-385.	1.3	32
69	<i>trans</i> -[Ru(CO) ₃] ²⁺ Selectively Targets the Histidine Residues of the $A\beta$ 1-28. Implications for New Alzheimer's Disease Treatments Based on Ruthenium Complexes. Inorganic Chemistry, 2010, 49, 4720-4722.	1.9	76
70	The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins. ChemMedChem, 2010, 5, 1989-1994.	1.6	40
71	[Au ₂ (phen) ₂ Me] ₂ (μ -O) ₂ (PF ₆) ₂ , a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties. ACS Medicinal Chemistry Letters, 2010, 1, 336-339.	1.3	79
72	Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. Chemical Communications, 2010, 46, 7001.	2.2	64

#	ARTICLE	IF	CITATIONS
73	Solution Behaviour and Biomolecular Interactions of Two Cytotoxic <i>trans</i> -Platinum(II) Complexes Bearing Aliphatic Amine Ligands. <i>Chemistry - A European Journal</i> , 2009, 15, 9139-9146.	1.7	21
74	Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 761-770.	1.1	98
75	Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 1139-1149.	1.1	119
76	Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. <i>Journal of Inorganic Biochemistry</i> , 2009, 103, 310-312.	1.5	30
77	Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs. <i>Coordination Chemistry Reviews</i> , 2009, 253, 1692-1707.	9.5	513
78	Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. <i>Metallomics</i> , 2009, 1, 434.	1.0	60
79	Clioquinol Decreases Amyloid- β^2 Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 423-440.	1.2	115
80	Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis. <i>Journal of Biological Inorganic Chemistry</i> , 2008, 13, 755-764.	1.1	35
81	The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose-Derived Stem Cells, Taken as a Model. <i>Chemistry and Biodiversity</i> , 2008, 5, 1513-1520.	1.0	9
82	Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 564-575.	1.5	249
83	Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 995-1006.	1.5	77
84	New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects <i>in vitro</i> : Mechanistic and pharmacological implications. <i>FEBS Letters</i> , 2008, 582, 844-847.	1.3	152
85	Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium(II)-Arene Compounds. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6773-6781.	2.9	258
86	Structural Characterization, Solution Studies, and DFT Calculations on a Series of Binuclear Gold(III) Oxo Complexes: Relationships to Biological Properties. <i>Inorganic Chemistry</i> , 2008, 47, 2368-2379.	1.9	102
87	Exploiting Soft and Hard X-Ray Absorption Spectroscopy to Characterize Metallodrug/Protein Interactions: the Binding of <i>trans</i> -RuCl ₄ (Im)(dimethylsulfoxide)] [ImH] (Im =) Tj ETQq1 1 0.784314 rgBT4@verloc		
88	Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity. <i>Natural Product Communications</i> , 2008, 3, 1934578X0800301.	0.2	7
89	Insights into the Molecular Mechanisms of Protein Platination from a Case Study: The Reaction of Anticancer Platinum(II) Iminoethers with Horse Heart Cytochrome c. <i>Biochemistry</i> , 2007, 46, 12220-12230.	1.2	51
90	ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. <i>Chemical Communications</i> , 2007, , 156-158.	2.2	137

#	ARTICLE	IF	CITATIONS
91	Unravelling the chemical nature of copper cuprizone. Dalton Transactions, 2007, , 2112.	1.6	51
92	New Copper(II)/Cyclic Tetrapeptide System That Easily Oxidizes to Copper(III) under Atmospheric Oxygen. Inorganic Chemistry, 2007, 46, 10038-10040.	1.9	29
93	Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased by trans-[Bis(2-amino-5-)] Tj ETQq1 1 0.784314 rgBT /Overlock 1 for a Ruthenium Compound. Journal of Medicinal Chemistry, 2007, 50, 5871-5874.	2.9	50
94	ESI-MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes. ChemMedChem, 2007, 2, 631-635.	1.6	86
95	Gold(III) compounds as anticancer drugs. Gold Bulletin, 2007, 40, 73-81.	3.2	128
96	Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c. Journal of Biological Inorganic Chemistry, 2007, 12, 1107-1117.	1.1	49
97	The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif. Journal of Inorganic Biochemistry, 2007, 101, 452-460.	1.5	34
98	Structural and Solution Chemistry, Antiproliferative Effects, and DNA and Protein Binding Properties of a Series of Dinuclear Gold(III) Compounds with Bipyridyl Ligands. Journal of Medicinal Chemistry, 2006, 49, 5524-5531.	2.9	189
99	The reaction of artemisinins with hemoglobin: A unified picture. Bioorganic and Medicinal Chemistry, 2006, 14, 2972-2977.	1.4	66
100	Exploring Metalloprotein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c. ChemMedChem, 2006, 1, 413-417.	1.6	91
101	Structure-Function Relationships within Keppler-Type Antitumor Ruthenium(III) Complexes: The Case of 2-Aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]. Inorganic Chemistry, 2005, 44, 4897-4899.	1.9	26
102	Mechanisms of Cytotoxicity of Selected Organogold(III) Compounds. Journal of Medicinal Chemistry, 2005, 48, 6761-6765.	2.9	125
103	The C2 variant of human serum transferrin retains the iron binding properties of the native protein. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 264-270.	1.8	18
104	Solution chemistry and cytotoxic properties of novel organogold(III) compounds. Bioorganic and Medicinal Chemistry, 2004, 12, 6039-6043.	1.4	76
105	The copper(II) binding properties of the cyclic peptide c(HGHK). Journal of Inorganic Biochemistry, 2004, 98, 2016-2021.	1.5	31